Showing 1 - 10 of 48
Persistent link: https://www.econbiz.de/10001780824
Persistent link: https://www.econbiz.de/10000908351
Persistent link: https://www.econbiz.de/10000994774
Persistent link: https://www.econbiz.de/10000994775
Persistent link: https://www.econbiz.de/10002379705
A patent only protects an innovator from others producing the same product, but it does not protect him from others producing better products under new patents. Therefore, one may divide up the source of competition facing an innovator into within-patent competition, which results from...
Persistent link: https://www.econbiz.de/10013225118
A patent only protects an innovator from others producing the same product, but it does not protect him from others producing better products under new patents. Therefore, one may divide up the source of competition facing an innovator into within-patent competition, which results from...
Persistent link: https://www.econbiz.de/10014029857
The social value of an innovation is comprised of the value to consumers and the value to innovators. We estimate that for the HIV/AIDS therapies that entered the market from the late 1980's onwards, innovators appropriated only 5% of the social surplus arising from these new technologies....
Persistent link: https://www.econbiz.de/10013234087
Congress enacted and renewed the Prescription Drug User Fee Acts (PDUFA) in 1992, and renewed it in 1997 and 2002, mandating FDA performance goals in reviewing and acting on drug applications within specified time periods. In turn, the FDA was permitted to levy user fees on drug sponsors...
Persistent link: https://www.econbiz.de/10013217967
Persistent link: https://www.econbiz.de/10003923781